#USA #Piscataway #AI Drug Discovery #GenScript Biotech #Gene-to-Protein

GenScript's Impressive First-Half 2026 Results

In a striking report released on August 18, 2026, GenScript Biotech Corporation (HKEX: 1548) disclosed its first-half financial performance, showcasing an extraordinary revenue growth of 27.3%. This notable increase results in approximately US$404.2 million, emphasizing the expanding impact of AI technologies within the pharmaceutical industry. The company's adjusted net profit skyrocketed by 203.3%, reaching about US$62.5 million, showcasing a remarkable improvement in both revenue and profitability across its operations.

Growth Driven by AI Drug Discovery

A highlight of GenScript's performance is the remarkable doubling of its AI-enabled drug discovery business, marking its third consecutive half-year of rapid growth characterized by heightened interest from biotechnology firms and pharmaceutical innovators. The Gene-to-Protein platform emerged as a leading figure within the GenScript Life Science Group, contributing about 66% to the revenue and playing a pivotal role in driving the company's expansion.

GenScript’s innovative Gene-to-Protein platform is designed to streamline the entire drug development process, integrating scientific expertise with automation and a wide-reaching manufacturing capacity. This comprehensive approach enables clients to efficiently validate drug candidates and expedite programs with competence and reliability, fulfilling a growing demand as AI increasingly influences the complexity and scale of drug discovery.

Leadership Insights

Sherry Shao, the Rotating CEO of GenScript, remarked, “Our first-half results reflect a strong execution across the portfolio, with core businesses significantly contributing to our revenue growth and profitability.” She further highlighted the immense long-term potential driven by AI advancements in life sciences, which is expected to elevate the demand for validation and development services within this sector.

Key Financial Highlights

In further detailing the first-half results for 2026, GenScript reported:

• - The Life Science Group generated an impressive revenue of approximately US$319.0 million, showing a growth of 28.8%.
• - Adjusted gross profit surged to approximately US$184.5 million, marking a 46.1% increase.
• - Adjusted operating profit skyrocketed to approximately US$94.0 million, reflecting a 102.8% growth.

GenScript's adaptive strategy has enabled it to not only respond to the expansive demands in AI drug discovery but also to expand its market capabilities and accommodate newer, more complex projects.

Investing in Future Growth

To sustain the upward trajectory, GenScript is making continued investments in its worldwide discovery and manufacturing network, focusing on expanding operational capabilities, shortening turnaround times, and enhancing its automation and digital workflows. As client projects grow progressively intricate and AI-driven, these investments are crucial in delivering consistent and scalable solutions.

ProBio and Bestzyme Performance

The ProBio segment has shown promising growth as well, with revenues rising by 34.2% from the previous year to about US$61.1 million. Furthermore, new orders surged by 54%, indicating a strong market demand, and the adjusted operating loss has been narrowed down by 22.5%. GenScript anticipates ProBio will achieve positive adjusted EBITDA by 2027.

In contrast, Bestzyme reported a revenue of approximately US$30.4 million, a growth of 7.4%, along with an adjusted gross profit increase of 14.0%, further supporting GenScript's growing influence across biopharmaceuticals.

Outlook for the Second Half of 2026

As GenScript advances into the latter half of 2026, the company retains a positive outlook backed by a solid foundation of demand and operational efficiency across all its key business segments. Furthermore, GenScript expects that ongoing investments in technology and automation will enable them to support larger, more sophisticated drug discovery programs, with both ProBio and Bestzyme poised for further long-term growth and customer engagement.

With these robust developments, GenScript is positioned as a vital partner in the infrastructure supporting the next wave of biotechnology and therapeutic innovation.